SPY открывает неделю гэпом вверх

Ближайший уровень поддержки по SPY – 200.80 уровень сопротивления – 201.20



Gapping up/down: DGLY +15% after guidance, CPWR +15%, FLWS 13%, and TMUS+3% on M&A news, TSLA +3% on upgrade; CONN -25% after earnings, metals and miners trading lower, OSIS -3% after dg

Gapping up
In reaction to strong earnings/guidance: DGLY +15.5%, FORM +2.4%, KFX +1.1%, (also announces acquisition of Softpro GmbH) ZNH +1%, GZT +0.7%.

M&A news: CPWR +15% (WSJ reporting that company is in sale discussions), FLWS +12.6% (signs definitive agreement to acquire Harry & David Holdings for $142.5 mln in cash), TMUS +2.8% (Illiad (ILIAY) in discussions with buyout firms regarding TMUS bid, according to reports), DG +1.7% (to raise bid for FDO for $80/share), TSL +1.4% (acquires Majority Stake in Yunnan Metallurgical New Energy), ARCP +0.8% (confirms Cole Corporate Income Trust entered into merger agreement relating to the sale of CCIT to Select Income REIT (SIR)), FDO +0.6% (Dollar General (DG) confirms enhanced proposal to acquire Family Dollar).

Select pharma/biotech related names showing strength: ELOS +10.5%, ZGNX +5.9% (reports that Zohydro ER demonstrates sustained 12-hour pain relief), ARNA +3.9%, NVS +3.5% (new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial, early results of upcoming presentations).


Other news: HGSH +43.2% (signed its second shanty area rebuilding project agreement with a budgeted investment over $750 mln), ASTI +21.2% (announces new common stock investment of $8.0 mln led by largest shareholder), SYNA +4.7% (positive Barron's mention), USG +3.5% (positive Barron's mention), ISNS +2.4% (in sympathy with DGLY), NXPI +2.2% (reports that Apple (AAPL) may partner with Visa (envy) and Mastercard (MA) for payment applications), DTV +1.9% (still checking), OWW +1.8% (reaches an agreement with American Airlines (AAL) to continue to offer American Airlines and US Airways (LCC) flights on all of its sites), BLDP +1.8% (appoints Randy MacEwen as President and Chief Executive Officer, effective October 6, 2014), PBA +1.2% (to acquire the Vantage pipeline system and Mistral Midstream's interest in the Saskatchewan Ethane Extraction Plant), NBG +0.9% (still checking), YHOO +0.8% (Alibaba.com to begin roadshow next week, according to reports).

Analyst comments: SPLS +4.9% (upgraded to Outperform from Neutral at Credit Suisse), SD +3.4% (upgraded to Buy at Stifel), CENX +3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), GRPN +2.9% (upgraded to Sector Perform at RBC Capital Mkts), STO +2.9% (upgraded to Buy from Hold at Deutsche Bank), TSLA +2.9% (upgraded to Buy from Hold at Stifel), DSKY +2.6% (initiated with a Overweight at Piper Jaffray), ACHN +2.6% (tgt raised to $15 from $11 at UBS), TS +2.4% (upgraded to Neutral from Sell), RCAP +1.9% (upgraded to Buy from Neutral at Citigroup), ZU +1.5% (upgraded to Buy from Fair Value at CRT Capital), ANET +1.3% (initiated with a Buy at Sun Trust Rbsn Humphrey), COG +1% (upgraded to Buy at Stifel), AAPL +0.8% (target raised to $120 from $105 at Piper Jaffray)

Gapping down
In reaction to disappointing earnings/guidance: CONN -25.5%, VIVO -0.6%.

Select pharma/biotechl related names showing weakness: AMPE -5.1% (announces update on the phase III, multicenter, double-blind STEP study of Ampion for osteoarthritis of the knee), GSK -1.6%, AZN -1.1%.

Select metals/mining stocks trading lower: GFI -2.5%, PAAS -2.4%, NEM -2.1%, GG -2%, GDX -1.8%, SLV -1.7%, GOLD -1.7%, GLD -1.6%, SLW -1.4%,.

Other news: EXEL -52.4% (announces results from the COMET-1 Phase 3 pivotal trial of Cabozantinib in men with metastatic castration-resistant prostate cancer), RIBT -17.4% (disclosed its Irgovel plant experienced a structural breakdown; co withdraws prior guidance), TWGP -11.9% (received a letter from the SEC stating that the SEC is conducting an investigation and attaching a subpoena for various documents), PT -2.7% (still checking), LXRX -1.3% (files for $150 mln mixed securities shelf offering), PXLW -1.2% (files $50 mln common stock shelf offering), HSBC -0.9% (stake sold by Fund Manager Neil Woodford, according to reports), CREE -0.7% (LED demand fell in Q3 QoQ, according to reports (not stock specific)).

Analyst comments: OSIS -3.1% (downgraded to Perform from Outperform at Oppenheimer), FNSR -2.5% (downgraded to Hold from Buy at Jefferies), EMES -1.7% (downgraded to Neutral at Robert W. Baird on valuation), FCX -0.5% (downgraded to Equal-Weight from Overweight).

Оригинал статьи: gtstocks.com/analytics-02-09-2014.html